Emicizumab for the prevention of bleeds in hemophilia A

References

• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–e47.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Merchan EC. Musculo-skeletal manifestations of haemophilia. Blood Rev. 2016 Sep;30(5):401–409. PubMed PMID: 27166435.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Merchan EC, Valentino LA. Orthopedic disorders of the knee in hemophilia: a current concept review. World J Orthop. 2016 Jun 18;7(6):370–375. PubMed PMID: 27335812; PubMed Central PMCID: PMCPMC4911520.
   PubMed Web of Science ®Google Scholar
• Gene therapy: concepts and methods. Few applications so far. Prescrire Int. 2009 Dec;18(104): 276–279. PubMed PMID: 20027718.
   PubMedGoogle Scholar
• Scheiflinger F, Dorner F. Recent advances in the understanding of the molecular biology of hemophilia A: possible implications towards a more effective therapeutic regime. Wien Klin Wochenschr. 1999 Mar 12;111(5):172–180. PubMed PMID: 10226347.
   PubMed Web of Science ®Google Scholar
• White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001 Mar;85(3):560. PubMed PMID: 11307831.
   PubMed Web of Science ®Google Scholar
• Inherited blood clotting disorders. Report of a WHO scientific group. World Health Organ Tech Rep Ser. 1972;504:1–48. PubMed PMID: 4628660.
   PubMedGoogle Scholar
• Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia. 2001 Sep;7(5):446–452. PubMed PMID: 11554930.
   PubMed Web of Science ®Google Scholar
• Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Blood. 2013 Nov 21;122(22):3568–3574. PubMed PMID: 24065241; PubMed Central PMCID: PMCPMC3837506.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. The choice of plasma-derived clotting factor concentrates. Baillieres Clin Haematol. 1996 Jun;9(2):273–290. PubMed PMID: 8800505.
   PubMedGoogle Scholar
• Monahan PE. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors. Hematology Am Soc Hematol Educ Program. 2015;2015:33–40. PubMed PMID: 26637698; eng.
   PubMedGoogle Scholar
• Orlova NA, Kovnir SV, Vorobiev II, et al. Blood Clotting Factor VIII: from Evolution to Therapy. Acta Naturae. 2013 Apr;5(2):19–39. PubMed PMID: 23819034; PubMed Central PMCID: PMCPMC3695351.
   PubMed Web of Science ®Google Scholar
• van Aken WG. Availability of clotting factor concentrates in genetically engineered form. Transfus Sci. 1998 Mar;19(1):9–15. PubMed PMID: 10182186.
   PubMedGoogle Scholar
• Young G, Mahlangu JN. Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016 Jul;22(Suppl 5):25–30. PubMed PMID: 27405672.
   PubMedGoogle Scholar
• Berntorp E, Andersson NG. Prophylaxis for hemophilia in the era of extended half-life factor VIII/factor IX products. Semin Thromb Hemost. 2016 Jul;42(5):518–525. PubMed PMID: 27096762.
   PubMed Web of Science ®Google Scholar
• Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia. 2014 May;20(Suppl 4):99–105. PubMed PMID: 24762284.
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Krishnan S, Auguste P, et al. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov;22(6):866–872. PubMed PMID: 27385432.
   PubMed Web of Science ®Google Scholar
• Young J, Grabell J, Rydz N, et al. Relationship between quality of life and coagulation factor level in hemophilia carriers: preliminary results. J Thromb Haemost. 2015 Jun 13;13:590. PubMed PMID: WOS:000356426903515.
   Web of Science ®Google Scholar
• Carcao M, Hilliard P, Escobar MA, et al. Optimising musculoskeletal care for patients with haemophilia. Eur J Haematol. 2015 Dec;95(Suppl 81):11–21. PubMed PMID: 26679393; eng.
   PubMedGoogle Scholar
• Poonnoose P, Carneiro JDA, Cruickshank AL, et al. Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage - the MUSFIH study. Haemophilia. 2017 Jul;23(4):538–546. PubMed PMID: 28574179.
   PubMed Web of Science ®Google Scholar
• Witmer CM. Low mortality from intracranial haemorrhage in paediatric patients with haemophilia. Haemophilia. 2015 Sep;21(5):e359–63. PubMed PMID: 26010533.
   PubMed Web of Science ®Google Scholar
• Rao SV, Harrington RA. Bleeding and mortality with dual antiplatelet therapy: the rashomon effect. J Am Coll Cardiol. 2017 Apr 25;69(16):2023–2025. PubMed PMID: 28427577.
   PubMed Web of Science ®Google Scholar
• Plug I, Van Der Bom JG, Peters M, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost. 2006 Mar;4(3):510–516. PubMed PMID: 16460432.
   PubMed Web of Science ®Google Scholar
• von Mackensen S, Kalnins W, Krucker J, et al. Haemophilia patients’ unmet needs and their expectations of the new extended half-life factor concentrates. Haemophilia. 2017 Jul;23(4):566–574. PubMed PMID: 28370896.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Cerquiera M, Srivastava A. Emerging therapies for haemophilia - Global perspective. Haemophilia. 2018 May;24 Suppl 6:15–21. PubMed PMID: 29878661.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med. 2018 Aug 30;379(9):811–822. PubMed PMID: 30157389.
   PubMed Web of Science ®Google Scholar
• Bardi E, Astermark J. Genetic risk factors for inhibitors in haemophilia A. Eur J Haematol. 2015 Feb;94 Suppl 77:7–10. PubMed PMID: 25560788.
   PubMed Web of Science ®Google Scholar
• DeKoven M, Karkare S, Lee WC, et al. Impact of haemophilia with inhibitors on caregiver burden in the United States. Haemophilia. 2014 Nov;20(6):822–830. PubMed PMID: 25273645.
   PubMed Web of Science ®Google Scholar
• Knight C, Dano AM, Kennedy-Martin T. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia. 2009 Mar;15(2):405–419. PubMed PMID: 19187191.
   PubMed Web of Science ®Google Scholar
• Stewart AJ, Hanley JP, Ludlam CA. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor. Blood Coagul Fibrinolysis. 1998 Mar;9(Suppl 1):S93–5. PubMed PMID: 9819036.
   PubMedGoogle Scholar
• Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743–754.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med. 2017 Aug 31;377(9):819–828. PubMed PMID: 28691885.
   PubMed Web of Science ®Google Scholar
• Pipe S J-YV, Shapiro A, et al. Emicizumab subcutaneous dosing every 4 weeks is safe and efficacious in the control of bleeding in persons with haemophilia A with and without inhibitors- results from the phase 3 HAVEN 4 study. In: Kessler M, editor. 2018 world congress of the World Federation Hemophilia; 2018 May 20-24; Glasgow, UK.
   Google Scholar
• Young G, Sidonio RF, Liesner R, et al. HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with hemophilia a with inhibitors. Blood. 2017;130(Suppl 1):85.
   Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017 Aug 31;377(9):809–818. PubMed PMID: 28691557; eng.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017 Jun 28;117(7):1348–1357. PubMed PMID: 28451690; PubMed Central PMCID: PMCPMC6292136.
   PubMed Web of Science ®Google Scholar
• Minami H, Nogami K, Soeda T, et al. The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity. Thromb Res. 2018 Jun;166:77–79. PubMed PMID: 29684725; eng.
   PubMed Web of Science ®Google Scholar
• Sampei Z, Igawa T, Soeda T, et al. Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity. MAbs. 2015;7(1):120–128. PubMed PMID: 25524207; PubMed Central PMCID: PMCPMC4622617. eng.
   PubMed Web of Science ®Google Scholar
• Yada K, Nogami K, Shinozawa K, et al. Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V. Br J Haematol. 2018 Aug 20;183:257–266. PubMed PMID: 30125997.
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017 Dec 7;130(23):2463–2468. PubMed PMID: 29042366.
   PubMed Web of Science ®Google Scholar
• Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016 May 26;374(21):2044–2053. PubMed PMID: 27223146; eng.
   PubMed Web of Science ®Google Scholar
• Uchida N, Sambe T, Yoneyama K, et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016 Mar 31;127(13):1633–1641. PubMed PMID: 26626991; PubMed Central PMCID: PMCPMC4817308. eng.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2018 Nov 14. PubMed PMID: 30427582. DOI:10.1111/hae.13618
   Google Scholar
• Shima M, Nogami K, Nagami S, et al. Every 2 weeks or every 4 weeks subcutaneous injection of emicizumab in pediatric patients with severe hemophilia a without inhibitors: a multi-center, open-label study in Japan (HOHOEMI study). Blood. 2018;132(Suppl1):1186.
   Google Scholar
• Young G, Liesner R, Sidonio RF, et al. Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia Α with inhibitors: results from the HAVEN 2 study. Haemophilia. 2018;132(Suppl1):632.
   Google Scholar
• Zimowski KL, Batsuli GM, Reding MT, et al. Maintaining perioperative hemostasis in patients with severe hemophilia A and inhibitors receiving emicizumab prophylaxis. Blood. 2018;132(Suppl 1):635.
   Google Scholar
• Patel A, Raimundo K, Stepule C, et al. Management of persons with hemophilia A with inhibitors after emicizumab approval. Blood. 2018;132(Suppl1):5020.
   Google Scholar
• Mahajerin A, Zhou Z-Y, Raimundo K, et al. Model of short and long-term outcomes of emicizumab prophylaxis treatment for persons with hemophilia Α. Blood. 2018;132(Suppl1):3511.
   Google Scholar
• Knoebl P, Sperr WR, Schellongowski P, et al. Emicizumab for the treatment of acquired hemophilia_A: lessons learned from 4 very different cases. Blood. 2018;132(Suppl1):2476.
   Google Scholar
• Batsuli GM, Zimowski KL, Tickle K, et al. The atlanta protocol: immune tolerance induction in pediatric patients with hemophilia a and inhibitors on emicizumab. Blood. 2018;132(Suppl1):634.
   Google Scholar
• Sidonio RF, Patel A, Corman S, et al. Model of the impact of delayed inhibitor development on cumulative breakthrough bleeds and costs in persons with hemophilia a receiving emicizumab prophylaxis. Blood. 2018;132(Suppl1):4710.
   Google Scholar
• Rebecca Kruse-Jarres MUC, Croteau SE, Jimenez-Yuste V, et al. Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2). Blood. 2017;130:89.
   Web of Science ®Google Scholar
• Stadler J, Naderer L, Beffort L, et al. Safety and immune responses after intradermal application of Porcilis PRRS in either the neck or the perianal region. PLoS One. 2018;13(9):e0203560. PubMed PMID: 30192831; PubMed Central PMCID: PMCPMC6128605 an employee of MSD Animal Health, which provided funding for the study. Dr. Kerstin Fiebig had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Funding from MSD Animal Health does not alter our adherence to PLOS ONE policies on sharing data and materials.
   PubMed Web of Science ®Google Scholar
• Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018 Nov 9;18(1):188. PubMed PMID: 30413151; PubMed Central PMCID: PMCPMC6234796.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Karim AF, Gorska-Kosicka M, et al. Anti-drug antibody formation induced by recombinant activated FVII analogue (vatreptacog alfa) - results from the phase 3 adept (TM) 2 trial in haemophilia patients with inhibitors. J Thromb Haemost. 2013 Jul;11:268. PubMed PMID: WOS:000331833601608.
   Web of Science ®Google Scholar
• Mahlangu J, Kuliczkowski K, Abdul Karim F, et al. Efficacy and safety of rVIII-SingleChain: results of a phase I/III multicenter clinical trial in severe hemophilia A. Blood. 2016 Jun 21. PubMed PMID: 27330001; Eng. DOI:10.1182/blood-2016-01-687434
   PubMedGoogle Scholar
• Mahlangu J, Paz P, Hardtke M, et al. TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 2016 Nov;22(6):873–879. PubMed PMID: 27501279.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16;123(3):317–325. PubMed PMID: 24227821; PubMed Central PMCID: PMCPMC3894491.
   PubMed Web of Science ®Google Scholar
• Mahlangu JN, Ragni M, Gupta N, et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 Jul 4;116(1):1–8. PubMed PMID: 26962852.
   PubMed Web of Science ®Google Scholar
• Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies. Blood. 2018;132(Suppl1):633.
   Google Scholar
• Hartmann R, Feenstra T, Valentino L, et al. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost. 2018 Jun 11;16:1580–1591. PubMed PMID: 29888855; eng.
   Web of Science ®Google Scholar
• Le Quellec S, Negrier C. Emicizumab should be prescribed independent of immune tolerance induction. Blood Adv. 2018 Oct 23;2(20):2783–2786. PubMed PMID: 30352952; PubMed Central PMCID: PMCPMC6199655.
   PubMed Web of Science ®Google Scholar
• Young G, Callaghan M, Dunn A, et al. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 Nov;11(11):835–846. PubMed PMID: 30278802.
   PubMed Web of Science ®Google Scholar
• Young G. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Adv. 2018 Oct 23;2(20):2780–2782. PubMed PMID: 30352951; PubMed Central PMCID: PMCPMC6199657.
   PubMed Web of Science ®Google Scholar
• Nogami K, Matsumoto T, Tabuchi Y, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. J Thromb Haemost. 2018 Jun;16(6):1078–1088. PubMed PMID: 29645406; eng.
   PubMed Web of Science ®Google Scholar
• Nogami K, Soeda T, Matsumoto T, et al. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost. 2018 Jul;16(7):1383–1390. PubMed PMID: 29734520; eng.
   PubMed Web of Science ®Google Scholar
• Ogiwara K, Nogami K, Matsumoto T, et al. A modified thrombin generation analysis to measure the plasma coagulation potency in the presence of anti-FIXa/FX bispecific antibody, emicizumab. Blood. 2018;132(Suppl1):1200.
   Google Scholar
• Pruner I, Zong Y, Mahmoud Hourani Soutari N, et al. Combined effect of by-pass agents and a sequence identical analogue of emicizumab on fibrin clot turbidity and structure in factor VIII deficient plasma. Blood. 2018;132(Suppl1):2473.
   Google Scholar
• Suster MA, Maji D, Nayak LV, et al. A novel point-of-care whole blood coagulation assay to monitor emicizumab therapy in patients with hemophilia. Blood. 2018;132(Suppl1):2475.
   Google Scholar
• Ogiwara K, Horiuchi H, Nogami K, et al. Assessment of emicizumab-driven clot stability in hemophilia a model. Blood. 2018;132(Suppl1):2478.
   Google Scholar
• Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia. 2018 May;24(3):344–347. PubMed PMID: 30070072.
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Miracle of haemophilia drugs: personal views about a few main players. Haemophilia. 2018 Jul;24(4):557–562. PubMed PMID: 29808952.
   PubMed Web of Science ®Google Scholar